This increase of HLA-DR−CD11b+CD33+ MDSCs may be mobilized and recruited during the active inflammatory process in SLE, because inflammation can lead to myelopoiesis [65] potentially giving rise to these intermediate stages of myeloid cells. Here, CD33 is linked to systemic lupus erythematosus.